Streetbeat News

Analyst Ratings

AVB

Mizuho analyst Haendel St. Juste maintains a Neutral rating on AvalonBay Communities (NYSE:AVB) and lowers the price target from $190 to $186.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2023 | 12:08 pm

GALT

Galectin Therapeutics, Inc. (NASDAQ:GALT) will present an update on its belapectin liver cirrhosis program at the 20th edition of the Discovery on Target meeting. The presentation will focus on the role of activated macrophages in liver cirrhosis and the potential of belapectin, a galectin-3 inhibitor, in treating the disease. Belapectin is currently in a Phase 2b/3 trial for the prevention of esophageal varices in NASH cirrhosis.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2023 | 12:08 pm

AIRC

Mizuho analyst Vikram Malhotra maintains a 'Buy' rating on Apartment Income REIT (NYSE:AIRC) but has lowered the price target from $40 to $33.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2023 | 12:07 pm

TGT

Stifel analyst Mark Astrachan has maintained a 'Hold' rating on Target (NYSE:TGT) and lowered the price target from $145 to $130.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2023 | 12:06 pm

WMT

Stifel analyst Mark Astrachan has maintained a 'Hold' rating on Walmart (NYSE:WMT) and raised the price target from $167 to $169.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2023 | 12:05 pm

MTN

JP Morgan analyst Brandt Montour maintains a Neutral rating on Vail Resorts (NYSE:MTN) and raises the price target from $231 to $280.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2023 | 12:04 pm

CMA

Odeon Capital analyst Dick Bove has downgraded Comerica (NYSE:CMA) from Buy to Hold and set a price target of $46.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2023 | 12:02 pm

ONCY

Oncolytics Biotech, Inc. (NASDAQ:ONCY) has been selected by the Pancreatic Cancer Action Network (PanCAN) to receive a $5 million Therapeutic Accelerator Award. The award is in recognition of Oncolytics' work on pelareorep, an investigational immunotherapy treatment for pancreatic cancer. The grant will fund the next stage of research, which includes a clinical trial of pelareorep in combination with modified FOLFIRINOX chemotherapy. If successful, the treatment may advance to late-stage clinical development through the PanCAN Precision Promise adaptive clinical trial platform.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2023 | 12:02 pm

RDFN

Over the past 3 months, 5 analysts have published their opinion on Redfin (NASDAQ:RDFN) stock. The company has an average price target of $11.4 with a high of $15.00 and a low of $10.00. The average price target has increased by 21.66% over the past month. The analysts' ratings are somewhat bearish.

Portfolio Pulse from Benzinga Insights

September 26, 2023 | 12:01 pm

SNAP

Over the past 3 months, 13 analysts have published their opinion on Snap (NYSE:SNAP) stock. The average price target is $9.62, implying an upside from the current price of $8.6. The average price target has increased by 4.0% over the past month.

Portfolio Pulse from Benzinga Insights

September 26, 2023 | 12:01 pm